BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 22, 2004
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Bioenvision (BIVN) Oppenheimer Cory Kasimov New Buy
Kasimov set a $16 target. He expects the company's clofarabine cancer compound will be approved by year end. BIVN closed Friday at $9.80, up $0.99 (11%) on the week.
CancerVax (CNVX) Janney Montgomery Scott Brian Rye New Buy
Rye set a $13 target. Within 18 months, he expects Phase...

Read the full 405 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >